ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2025
Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.
Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus. Objective: This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE. Case presentation: In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area. Conclusion: Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.